Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | NAE1 | Q13564 | 2/20 | 0.40 |
| ▸ | UBA3 | Q8TBC4 | 2/20 | 0.40 |
| ▸ | ATG7 | O95352 | 2/20 | 0.40 |
| ▸ | UBA6 | A0AVT1 | 1/20 | 0.40 |
| ▸ | UBA7 | P41226 | 1/20 | 0.40 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ALB | P02768 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12566844 | 0.89 | BCHE (0.44) | BCHECYP1A2NAE1UBA3ATG7 | |
| SCHEMBL12652507 | 0.88 | BCHE (0.45) | BCHECYP1A2NAE1UBA3ATG7 | |
| SCHEMBL12567213 | 0.88 | BCHE (0.43) | BCHECYP1A2NAE1UBA3ATG7 | |
| SCHEMBL12566427 | 0.87 | DNPH1 (0.47) | BCHECYP1A2NAE1UBA3ATG7 | |
| SCHEMBL12566878 | 0.87 | BCHE (0.42) | BCHECYP1A2NAE1UBA3ATG7 | |
| SCHEMBL12566441 | 0.84 | BCHE (0.43) | BCHECYP1A2NAE1UBA3ATG7 | |
| SCHEMBL12652428 | 0.83 | BCHE (0.43) | BCHECYP1A2NAE1UBA3ATG7 | |
| SCHEMBL12566833 | 0.82 | BCHE (0.41) | BCHECYP1A2NAE1UBA3ATG7 | |
| SCHEMBL12567198 | 0.81 | ATG7 (0.46) | BCHECYP1A2NAE1UBA3ATG7 | |
| SCHEMBL13773372 | 0.80 | BCHE (0.54) | BCHECYP1A2ALDH1A1LMNAALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-7951810-B2 | Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | BCHE 24/4885CYP1A2 644/4885NAE1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.